N6-methyladenosine RNA landscape in the aged mouse hearts
ObjectiveCardiac aging is a major risk factor for the development of cardiovascular diseases. Although evidence suggests an association between N6-methyladenosine (m6A) modification and numerous cardiovascular diseases, its role in cardiac aging remains unclear. This study was conducted to elucidate...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1563364/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849688713567666176 |
|---|---|
| author | Xia Jing Xia Jing Yingming Li Zhaofu Liao Jing-Yu Wu Zi-Yang Xu Zhi-Peng Yang Hai-Liang Mo Shun Xu Xinguang Liu Zhuguo Wu Jun Tao Xing-Dong Xiong |
| author_facet | Xia Jing Xia Jing Yingming Li Zhaofu Liao Jing-Yu Wu Zi-Yang Xu Zhi-Peng Yang Hai-Liang Mo Shun Xu Xinguang Liu Zhuguo Wu Jun Tao Xing-Dong Xiong |
| author_sort | Xia Jing |
| collection | DOAJ |
| description | ObjectiveCardiac aging is a major risk factor for the development of cardiovascular diseases. Although evidence suggests an association between N6-methyladenosine (m6A) modification and numerous cardiovascular diseases, its role in cardiac aging remains unclear. This study was conducted to elucidate the role of m6A modification in cardiac aging and the molecular mechanisms involved.MethodsGlobal methylation levels and the expression of major m6A regulators were compared between young and aged hearts. Transcriptome-wide m6A landscape analysis was conducted using methylated RNA immunoprecipitation sequencing (MeRIP-seq) and RNA sequencing (RNA-seq) to identify aberrant m6A peaks. Furthermore, gene set enrichment analysis (GSEA) was performed to identify gene sets associated with cardiac aging. Functional validation of key molecules was carried out through in vitro experiments.ResultsThe overall m6A level remained constant; however, the expression of the methyltransferase METTL14 and the demethyltransferase FTO were significantly upregulated in aged hearts. Knockdown of METTL14 alleviated H2O2-induced senescence phenotypes, as reflected by a reduction in the number of SA-β-gal positive cells and a decrease in p21 expression. Compared with young hearts, the dysregulated m6A peaks were significantly enriched in genes associated with dilated cardiomyopathy, hypertrophic cardiomyopathy, and the PI3K-Akt signaling pathway. GSEA showed that these genes were enriched in the aging of heart and aorta cardiomyocytes. Additionally, 255 genes with siginificantly changed of both m6A peaks and RNA expression were identified by combining MeRIP-seq and RNA-seq data. Among these genes, EFEMP1 was significantly upregulated in aged hearts, accompanied by enhanced m6A modification. Treatment with the methyltransferase inhibitor cycloleucine significantly suppressed the expression level of EFEMP1. In AC16 cells, silencing EFEMP1 suppressed H2O2-induced cell senescence. Furthermore, we found a positive correlation between METTL14 and EFEMP1 in multiple datasets related to cardiac aging.ConclusionOur findings indicate that m6A modification plays an essential role in the process of cardiac aging. EFEMP1 may serve as a potential new therapeutic target for age-related cardiac diseases. |
| format | Article |
| id | doaj-art-5bd0bded7c7c4e62b76242b94f38a28b |
| institution | DOAJ |
| issn | 2297-055X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj-art-5bd0bded7c7c4e62b76242b94f38a28b2025-08-20T03:21:52ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2025-06-011210.3389/fcvm.2025.15633641563364N6-methyladenosine RNA landscape in the aged mouse heartsXia Jing0Xia Jing1Yingming Li2Zhaofu Liao3Jing-Yu Wu4Zi-Yang Xu5Zhi-Peng Yang6Hai-Liang Mo7Shun Xu8Xinguang Liu9Zhuguo Wu10Jun Tao11Xing-Dong Xiong12Dongguan Key Laboratory of Aging and Anti-Aging, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, ChinaClinical Research Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, ChinaDongguan Key Laboratory of Aging and Anti-Aging, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, ChinaDongguan Key Laboratory of Aging and Anti-Aging, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, ChinaDongguan Key Laboratory of Aging and Anti-Aging, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, ChinaDongguan Key Laboratory of Aging and Anti-Aging, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, ChinaDongguan Key Laboratory of Aging and Anti-Aging, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, ChinaDepartment of Cardiology, The First Dongguan Affiliated Hospital of Guangdong Medical University, Dongguan, Guangdong, ChinaDongguan Key Laboratory of Aging and Anti-Aging, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, ChinaDongguan Key Laboratory of Aging and Anti-Aging, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, ChinaDongguan Key Laboratory of Aging and Anti-Aging, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, ChinaDepartment of Hypertension and Vascular Disease, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, ChinaDongguan Key Laboratory of Aging and Anti-Aging, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, ChinaObjectiveCardiac aging is a major risk factor for the development of cardiovascular diseases. Although evidence suggests an association between N6-methyladenosine (m6A) modification and numerous cardiovascular diseases, its role in cardiac aging remains unclear. This study was conducted to elucidate the role of m6A modification in cardiac aging and the molecular mechanisms involved.MethodsGlobal methylation levels and the expression of major m6A regulators were compared between young and aged hearts. Transcriptome-wide m6A landscape analysis was conducted using methylated RNA immunoprecipitation sequencing (MeRIP-seq) and RNA sequencing (RNA-seq) to identify aberrant m6A peaks. Furthermore, gene set enrichment analysis (GSEA) was performed to identify gene sets associated with cardiac aging. Functional validation of key molecules was carried out through in vitro experiments.ResultsThe overall m6A level remained constant; however, the expression of the methyltransferase METTL14 and the demethyltransferase FTO were significantly upregulated in aged hearts. Knockdown of METTL14 alleviated H2O2-induced senescence phenotypes, as reflected by a reduction in the number of SA-β-gal positive cells and a decrease in p21 expression. Compared with young hearts, the dysregulated m6A peaks were significantly enriched in genes associated with dilated cardiomyopathy, hypertrophic cardiomyopathy, and the PI3K-Akt signaling pathway. GSEA showed that these genes were enriched in the aging of heart and aorta cardiomyocytes. Additionally, 255 genes with siginificantly changed of both m6A peaks and RNA expression were identified by combining MeRIP-seq and RNA-seq data. Among these genes, EFEMP1 was significantly upregulated in aged hearts, accompanied by enhanced m6A modification. Treatment with the methyltransferase inhibitor cycloleucine significantly suppressed the expression level of EFEMP1. In AC16 cells, silencing EFEMP1 suppressed H2O2-induced cell senescence. Furthermore, we found a positive correlation between METTL14 and EFEMP1 in multiple datasets related to cardiac aging.ConclusionOur findings indicate that m6A modification plays an essential role in the process of cardiac aging. EFEMP1 may serve as a potential new therapeutic target for age-related cardiac diseases.https://www.frontiersin.org/articles/10.3389/fcvm.2025.1563364/fullm6A RNA methylationcardiac agingMETTL14FTOEFEMP1cardiac diseases |
| spellingShingle | Xia Jing Xia Jing Yingming Li Zhaofu Liao Jing-Yu Wu Zi-Yang Xu Zhi-Peng Yang Hai-Liang Mo Shun Xu Xinguang Liu Zhuguo Wu Jun Tao Xing-Dong Xiong N6-methyladenosine RNA landscape in the aged mouse hearts Frontiers in Cardiovascular Medicine m6A RNA methylation cardiac aging METTL14 FTO EFEMP1 cardiac diseases |
| title | N6-methyladenosine RNA landscape in the aged mouse hearts |
| title_full | N6-methyladenosine RNA landscape in the aged mouse hearts |
| title_fullStr | N6-methyladenosine RNA landscape in the aged mouse hearts |
| title_full_unstemmed | N6-methyladenosine RNA landscape in the aged mouse hearts |
| title_short | N6-methyladenosine RNA landscape in the aged mouse hearts |
| title_sort | n6 methyladenosine rna landscape in the aged mouse hearts |
| topic | m6A RNA methylation cardiac aging METTL14 FTO EFEMP1 cardiac diseases |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1563364/full |
| work_keys_str_mv | AT xiajing n6methyladenosinernalandscapeintheagedmousehearts AT xiajing n6methyladenosinernalandscapeintheagedmousehearts AT yingmingli n6methyladenosinernalandscapeintheagedmousehearts AT zhaofuliao n6methyladenosinernalandscapeintheagedmousehearts AT jingyuwu n6methyladenosinernalandscapeintheagedmousehearts AT ziyangxu n6methyladenosinernalandscapeintheagedmousehearts AT zhipengyang n6methyladenosinernalandscapeintheagedmousehearts AT hailiangmo n6methyladenosinernalandscapeintheagedmousehearts AT shunxu n6methyladenosinernalandscapeintheagedmousehearts AT xinguangliu n6methyladenosinernalandscapeintheagedmousehearts AT zhuguowu n6methyladenosinernalandscapeintheagedmousehearts AT juntao n6methyladenosinernalandscapeintheagedmousehearts AT xingdongxiong n6methyladenosinernalandscapeintheagedmousehearts |